Table 2.
Plasma sphingolipid levels by autopsy-confirmed pathology group
| Plasma sphingolipid | CN (N = 21) |
High likelihood DLB (N = 13) |
Intermediate-likelihood DLB (N = 17) |
AD (N = 18) |
X2 | 4-group Comparison P value |
|---|---|---|---|---|---|---|
| Median (IQR)/N (%) | Median (IQR)/N (%) | Median (IQR)/N (%) | Median (IQR)/N (%) | |||
| Sphingosine | 0.008 (0.004, 0.011) | 0.006 (0.005, 0.009) | 0.009 (0.006, 0.011) | 0.007 (0.004, 0.011) | 1.49 | .686 |
| Sphinganine | 0.007 (0.004, 0.011) | 0.004 (0.004, 0.007) | 0.007 (0.005, 0.008) | 0.006 (0.005, 0.008) | 3.39 | .335 |
| S1P | 2.04 (1.17, 3.34) | 2.04 (1.77, 2.28) | 3.01 (2.03, 3.92) | 2.15 (1.45, 2.92) | 4.95 | .175 |
| Ceramides | ||||||
| 16:0 | 0.47 (0.38, 0.52) | 0.603 (0.50, 0.66)∗† | 0.49 (0.44, 0.57) | 0.57 (0.49, 0.63)‡ | 11.18 | .011 |
| 18:1 | 0.02 (0.02, 0.03) | 0.033 (0.02, 0.04)∗† | 0.03 (0.02, 0.03) | 0.03 (0.02, 0.04)∗ | 12.31 | .006 |
| 18:0 | 0.08 (0.06, 0.10) | 0.13 (0.08, 0.15) | 0.11 (0.06, 0.12) | 0.11 (0.09, 0.15) | 6.70 | .082 |
| 20:0 | 0.17 (0.13, 0.21) | 0.24 (0.17, 0.27)‡† | 0.16 (0.12, 0.20) | 0.23 (0.18, 0.27)∗§ | 12.74 | .005 |
| 24:1 | 0.80 (0.70, 0.96) | 1.06 (0.78, 1.36)‡† | 0.78 (0.65, 0.87) | 1.06 (0.82, 1.20)‡† | 11.18 | .011 |
| 24:0 | 2.34 (1.97, 2.61) | 2.33 (1.41, 2.64) | 1.89 (1.68, 2.26) | 2.39 (1.82, 2.97) | 2.92 | .405 |
| Monohexosylceramides | ||||||
| 18:0 | 0.18 (0.11, 0.26) | 0.23 (0.19, 0.32) | 0.18 (0.15, 0.23) | 0.22 (0.19, 0.27) | 7.22 | .065 |
| 18:1 | 0.01 (0.01, 0.02) | 0.02 (0.02, 0.04)∗† | 0.01 (0.01, 0.02) | 0.02 (0.02, 0.03)∗† | 14.08 | .003 |
| 24:1 | 0.65 (0.48, 0.77) | 0.89 (0.78, 1.07)∗† | 0.74 (0.71, 0.89) | 0.82 (0.65, 0.97)‡ | 13.12 | .004 |
Abbreviations: CN, cognitively normal with normal aging pathology; IQR, interquartile range; DLB, Dementia with Lewy Bodies; AD, Dementia with Alzheimer's disease pathology; S1P, Sphingosine-1-Phosphate.
∗
P < .01 versus CN.
†
P < .05 versus intermediate-likelihood DLB.
‡
P < .05 versus CN.
§
P < .001 versus intermediate-likelihood DLB.